Skip to content
Inciteful Med

Living with FHH1: Monitoring and the 'No-Surgery' Rule

Last updated:

The standard of care for Familial Hypocalciuric Hypercalcemia Type 1 (FHH1) is active observation, not parathyroid surgery. Because FHH1 is a genetic change to the body's calcium set-point, surgery is ineffective. Most patients live full lives with simple yearly monitoring of blood and bones.

Key Takeaways

  • • The standard treatment for FHH1 is regular observation rather than active medical intervention or surgery.
  • • Parathyroid surgery is highly ineffective for FHH1 because the condition is a systemic genetic trait, not a localized tumor.
  • • Routine monitoring for FHH1 should include yearly blood work, bone density scans, and symptom check-ins.
  • • Medications like Cinacalcet are rarely needed but can help lower calcium levels in patients who develop severe symptoms.
  • • Patients with FHH1 should be aware of rare but possible long-term complications like osteoporosis, chondrocalcinosis, and pancreatitis.

For most patients with Familial Hypocalciuric Hypercalcemia Type 1 (FHH1), the most important “treatment” is actually no treatment at all [1][2]. Because FHH1 is a lifelong genetic trait where your body has simply chosen a higher “normal” for calcium, the standard of care is observation (regular monitoring) rather than active medical intervention [3][4].

Why Surgery is Not the Answer

In other conditions like Primary Hyperparathyroidism (PHPT), a small tumor on the parathyroid gland is the problem, and removing it is curative. FHH1 is different. It is a systemic “set-point” issue affecting every calcium-sensing cell in your body [5][3].

Because of this, parathyroid surgery (parathyroidectomy) is ineffective for FHH1 [6][7]. Studies show that about 83% of FHH1 patients who undergo surgery still have high calcium levels just one year later [6]. The remaining 17% do not represent “cures”; their calcium drops are usually temporary due to surgical shock or damage, eventually rising again [6]. Surgery does not fix the genetic “thermostat” and should be avoided to prevent unnecessary risks and recovery [8][9].

How to Monitor Your Health

While FHH1 is considered a benign condition (meaning it is generally stable, though it requires monitoring for specific complications over time), a small subset of patients may develop certain complications over many decades [3][10].

While you may not need active treatment, you should have a clear monitoring plan with your endocrinologist. A typical monitoring schedule might include:

  • Yearly Blood Work: To check your blood calcium, PTH, and kidney function (creatinine).
  • Bone Density (DEXA) Scans: To monitor for osteoporosis. While many FHH1 patients have healthy bones, some studies have noted a higher-than-average rate of bone fractures (14%) or osteoporosis (16%) in older adults [10].
  • Symptom Check-ins: Discuss any new joint pain, which can be a sign of chondrocalcinosis (calcium crystal deposits in the joints, found in about 22% of adult patients) [10][11]. You should also report any severe abdominal pain, as pancreatitis (inflammation of the pancreas) is a rare but documented risk [4][12].

When is Treatment Needed?

Medical treatment is rarely required, but it may be considered if a patient is severely symptomatic or develops specific complications, such as certain heart rhythm issues (like a short QT interval) [13][14].

The primary medications used are called calcimimetics (such as Cinacalcet) [15][16].

  • How they work: Think of these drugs as “glasses” for your calcium sensors. They bind to the CaSR protein and make it more sensitive to the calcium already in your blood [15][17].
  • The result: Once the sensors can “see” the calcium better, the parathyroid glands stop overproducing hormone, and blood calcium levels begin to drop toward a more typical range [18][14].

For the vast majority of people, however, simply knowing the diagnosis is enough. You can live a full, healthy life with FHH1 by simply monitoring your levels and ensuring that any future doctors understand that your “high” calcium is actually your body’s personal “normal” [3][19].

Return to the Home Page.

Frequently Asked Questions

Why is parathyroid surgery not recommended for FHH1?
Unlike other high calcium conditions caused by a tumor, FHH1 is a genetic trait affecting calcium sensors throughout your entire body. Surgery does not fix this genetic set-point, and most patients still have high calcium levels after the procedure.
What kind of monitoring is needed if I have FHH1?
Your endocrinologist will typically recommend yearly blood work to check your calcium, parathyroid hormone, and kidney function. You should also have periodic bone density scans and report any new joint or abdominal pain.
Are medications ever used to treat FHH1?
While rarely needed, medications called calcimimetics, such as Cinacalcet, can be prescribed if you develop severe symptoms or complications. These drugs help your body's calcium sensors better detect blood calcium, causing levels to drop toward a more typical range.
What are the long-term complications of FHH1?
FHH1 is generally benign, but some patients may develop complications over decades. These can include osteoporosis, calcium crystal deposits in the joints causing pain (chondrocalcinosis), or rarely, inflammation of the pancreas (pancreatitis).

Questions for Your Doctor

  • • Since FHH1 is generally benign, what is the 'wait and see' monitoring schedule you recommend for my blood and bone health?
  • • Why is parathyroid surgery ineffective for FHH1 compared to other types of high calcium conditions?
  • • Are my current symptoms severe enough to consider medications like Cinacalcet, or is observation still the best path?
  • • Do I have any risk factors for long-term complications like chondrocalcinosis or pancreatitis that we should monitor?
  • • If I were to develop severe symptoms in the future, how would a calcimimetic drug help my specific CASR mutation?

Questions for You

  • • How do I feel about the 'observation' approach? Does knowing my condition is usually harmless make me feel more comfortable with not taking medication?
  • • Have I ever had unexplained joint pain or a history of pancreatitis that I should mention to my doctor now that I have an FHH1 diagnosis?
  • • Am I prepared to explain to other doctors (like surgeons) that my high calcium is genetic and should not be treated with parathyroid surgery?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Parathyroid hormone-dependent familial hypercalcemia with low measured PTH levels and a presumptive novel pathogenic mutation in CaSR.

    Mahajan A, Buse J, Kline G

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2020; (31(1)):203-207 doi:10.1007/s00198-019-05170-9.

    PMID: 31641801
  2. 2

    Familial hypocalciuric hypercalcemia in an infant: diagnosis and management quandaries.

    Goldsweig B, Turk Yilmaz RS, Ravindranath Waikar A, et al.

    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2024; (39(10)):1406-1411 doi:10.1093/jbmr/zjae137.

    PMID: 39163488
  3. 3

    Genetics of hereditary forms of primary hyperparathyroidism.

    English KA, Lines KE, Thakker RV

    Hormones (Athens, Greece) 2024; (23(1)):3-14 doi:10.1007/s42000-023-00508-9.

    PMID: 38038882
  4. 4

    Nephrotic Syndrome Complicated with Familial Hypocalciuric Hypercalcemia in an Infant: A Case Report and Comprehensive Literature Review.

    Yu M, Xue M, Fan X, et al.

    Alternative therapies in health and medicine 2024;.

    PMID: 38702153
  5. 5

    Rare diseases caused by abnormal calcium sensing and signalling.

    Tőke J, Czirják G, Enyedi P, Tóth M

    Endocrine 2021; (71(3)):611-617 doi:10.1007/s12020-021-02620-5.

    PMID: 33528764
  6. 6

    Novel mutations of the calcium-sensing receptor impede differential diagnosis of primary hyperparathyroidism and familial hypocalciuric hypercalcemia.

    Bhangu JS, Baumgartner-Parzer S, Hargitai L, et al.

    Gland surgery 2022; (11(1)):12-22 doi:10.21037/gs-21-577.

    PMID: 35242665
  7. 7

    Familial hypocalciuric hypercalcemia caused by homozygous CaSR gene mutation: A case report of a family.

    Wang F, Hu J, Mei C, et al.

    Medicine 2020; (99(35)):e21940 doi:10.1097/MD.0000000000021940.

    PMID: 32871939
  8. 8

    A case of familial hypocalciuric hypercalcemia type 1 due to CASR p.Pro55Leu mutation.

    Sumida A, Iizuka K, Kato T, et al.

    BMC endocrine disorders 2022; (22(1)):164 doi:10.1186/s12902-022-01077-5.

    PMID: 35733207
  9. 9

    Multiple endocrine neoplasia phenocopy revealed as a co-occurring neuroendocrine tumor and familial hypocalciuric hypercalcemia type 3.

    Hovden S, Jespersen ML, Nissen PH, et al.

    Clinical case reports 2016; (4(10)):922-927 doi:10.1002/ccr3.657.

    PMID: 27761240
  10. 10

    Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: A multicentre study of 77 adult patients.

    Mouly C, Vargas-Poussou R, Lienhardt A, et al.

    Clinical endocrinology 2020; (93(3)):248-260 doi:10.1111/cen.14211.

    PMID: 32347971
  11. 11

    Case Report: Familial hypocalciuric hypercalcemia type 1 with a novel mutation combined with Gitelman syndrome and a review of the literature.

    He T, Li X, Li G, et al.

    Frontiers in endocrinology 2025; (16()):1503128 doi:10.3389/fendo.2025.1503128.

    PMID: 40070587
  12. 12

    A Rare Case of Familial Hypocalciuric Hypercalcemia in Patient With Pancreatitis.

    Khan MI, Jain T, Abid MM, et al.

    Journal of community hospital internal medicine perspectives 2025; (15(4)):66-68 doi:10.55729/2000-9666.1497.

    PMID: 40757212
  13. 13

    Successful use of cinacalcet to treat parathyroid-related hypercalcemia in two pediatric patients.

    Mogas E, Campos-Martorell A, Clemente M, et al.

    Endocrinology, diabetes & metabolism case reports 2018; (2018()).

    PMID: 29899992
  14. 14

    Cinacalcet Reverses Short QT Interval in Familial Hypocalciuric Hypercalcemia Type 1.

    Cuny T, Romanet P, Goldsworthy M, et al.

    The Journal of clinical endocrinology and metabolism 2024; (109(2)):549-556 doi:10.1210/clinem/dgad494.

    PMID: 37602721
  15. 15

    [Pharmacological characteristics of drugs targeted on calcium-sensing receptor.-properties of cinacalcet hydrochloride as allosteric modulator].

    Nagano N, Tsutsui T

    Clinical calcium 2016; (26(6)):839-50.

    PMID: 27230839
  16. 16

    Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody.

    Makita N, Ando T, Sato J, et al.

    JCI insight 2019; (4(8)).

    PMID: 30996138
  17. 17

    Allosteric modulation and G-protein selectivity of the Ca2+-sensing receptor.

    He F, Wu CG, Gao Y, et al.

    Nature 2024; (626(8001)):1141-1148 doi:10.1038/s41586-024-07055-2.

    PMID: 38326620
  18. 18

    Familial hypocalciuric hypercalcemia and related disorders.

    Lee JY, Shoback DM

    Best practice & research. Clinical endocrinology & metabolism 2018; (32(5)):609-619 doi:10.1016/j.beem.2018.05.004.

    PMID: 30449544
  19. 19

    Severe Symptomatic Hypercalcemia in a Patient With Familial Hypocalciuric Hypercalcemia.

    Kurian R, Madegowda Chandrashekar G, Antony MA, et al.

    Cureus 2021; (13(11)):e20057 doi:10.7759/cureus.20057.

    PMID: 34993031

This page explains FHH1 management and monitoring for educational purposes only. Always consult your endocrinologist regarding your specific condition and before making any changes to your care plan.

Stay up to date

Get notified when new research about Familial hypocalciuric hypercalcemia type 1 is published.

No spam. Unsubscribe anytime.